208 related articles for article (PubMed ID: 22896751)
1. The discovery of cancer/testis antigens by autologous typing with T cell clones and the evolution of cancer vaccines.
Jäger E; Knuth A
Cancer Immun; 2012; 12():6. PubMed ID: 22896751
[No Abstract] [Full Text] [Related]
2. The journey from autologous typing to SEREX, NY-ESO-1, and cancer/testis antigens.
Chen YT
Cancer Immun; 2012; 12():8. PubMed ID: 22896753
[No Abstract] [Full Text] [Related]
3. Tumor-specific shared antigenic peptides recognized by human T cells.
Van Der Bruggen P; Zhang Y; Chaux P; Stroobant V; Panichelli C; Schultz ES; Chapiro J; Van Den Eynde BJ; Brasseur F; Boon T
Immunol Rev; 2002 Oct; 188():51-64. PubMed ID: 12445281
[TBL] [Abstract][Full Text] [Related]
4. Cancer-testis antigens: targets for cancer immunotherapy.
Chen YT; Old LJ
Cancer J Sci Am; 1999; 5(1):16-7. PubMed ID: 10188055
[No Abstract] [Full Text] [Related]
5. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
Seremet T; Brasseur F; Coulie PG
Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282
[TBL] [Abstract][Full Text] [Related]
6. Calling cancer's bluff with neoantigen vaccines.
DeWeerdt S
Nature; 2017 Dec; 552(7685):S76-S77. PubMed ID: 29293229
[No Abstract] [Full Text] [Related]
7. B7-1 gene-modified tumor cell vaccines.
Antonia SJ
Curr Opin Mol Ther; 1999 Feb; 1(1):50-6. PubMed ID: 11249684
[No Abstract] [Full Text] [Related]
8. The genealogy of SEREX.
Pfreundschuh M
Cancer Immun; 2012; 12():7. PubMed ID: 22896752
[No Abstract] [Full Text] [Related]
9. Antigens recognized by T-lymphocytes on human tumours.
Coulie PG; Van den Eynde BJ; van der Bruggen P; Van Pel A; Boon T
Biochem Soc Trans; 1997 May; 25(2):544-8. PubMed ID: 9191153
[No Abstract] [Full Text] [Related]
10. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy.
Scanlan MJ; Gure AO; Jungbluth AA; Old LJ; Chen YT
Immunol Rev; 2002 Oct; 188():22-32. PubMed ID: 12445278
[TBL] [Abstract][Full Text] [Related]
11. [Tumor vaccines-therapeutic vaccination against cancer].
Rammensee HG; Löffler MW; Walz JS; Bokemeyer C; Haen SP; Gouttefangeas C
Internist (Berl); 2020 Jul; 61(7):690-698. PubMed ID: 32462251
[TBL] [Abstract][Full Text] [Related]
12. The identification of cancer antigens: impact on the development of cancer vaccines.
Rosenberg SA
Cancer J; 2000 Apr; 6 Suppl 2():S142-9. PubMed ID: 10803829
[No Abstract] [Full Text] [Related]
13. [Identification of tumor antigens: strategies and perspectives].
Jäger D; Zippelius A; Knuth A
Praxis (Bern 1994); 2004 Sep; 93(39):1584-8. PubMed ID: 15500242
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic cancer/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy.
Yang P; Meng M; Zhou Q
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188558. PubMed ID: 33933558
[TBL] [Abstract][Full Text] [Related]
15. The Cancer Vaccine Collaborative: a new model of coordinated discovery.
O'Donnell-Tormey J; McDermott EA
Cancer Immun; 2012; 12():10. PubMed ID: 22896755
[No Abstract] [Full Text] [Related]
16. The role of vaccines in cancer prevention.
Khleif SN; Frederickson H
Cancer Treat Res; 2001; 106():283-306. PubMed ID: 11225007
[No Abstract] [Full Text] [Related]
17. Human tumor antigens recognized by T lymphocytes.
Boon T; van der Bruggen P
J Exp Med; 1996 Mar; 183(3):725-9. PubMed ID: 8642276
[No Abstract] [Full Text] [Related]
18. In vivo tracking of tumor-specific T cells.
Yee C; Riddell SR; Greenberg PD
Curr Opin Immunol; 2001 Apr; 13(2):141-6. PubMed ID: 11228405
[TBL] [Abstract][Full Text] [Related]
19. Cancer vaccines: progress reveals new complexities.
Yu Z; Restifo NP
J Clin Invest; 2002 Aug; 110(3):289-94. PubMed ID: 12163445
[No Abstract] [Full Text] [Related]
20. Antitumour immune response and cancer vaccination: the critical role of dendritic cells.
Kochman S; Bernard J
Curr Med Res Opin; 1999; 15(4):321-6. PubMed ID: 10640266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
